New Greek Legislation Imposes Onerous Restrictions on Industrial Hemp and CBD Sector

Greece has introduced Law 5302/2026, a new legislative framework that significantly restricts the retail sale and possession of low-THC hemp flowers and CBD products. While intended to combat synthetic cannabinoids, the law effectively removes natural, non-intoxicating hemp from the market and limits distribution to pharmacies and specialized stores. This shift creates significant legal uncertainty for investors and entrepreneurs, potentially undermining Greece's goal of becoming a regional leader in the European cannabis and hemp industries.

Greece’s recent amendments under Law 5302/2026 represent a major policy shift that threatens the country’s burgeoning industrial hemp and CBD sectors. Despite legalizing industrial hemp in 2016 and medical cannabis in 2018, the new legislation imposes a blanket ban on the retail sale, possession, and use of hemp flowers containing less than 0.3% THC. This move targets natural agricultural commodities that are legally traded across the European Union, ostensibly to curb the spread of synthetic psychoactive cannabinoids. However, critics argue that by failing to distinguish between compliant natural products and illicit synthetics, the government is reverting to prohibition-era thinking that harms legitimate businesses.

The regulatory changes also tighten the distribution network for CBD products, moving toward a model that restricts sales primarily to licensed cannabis stores and pharmacies. This creates immediate instability for health food stores, organic retailers, and wellness outlets that have operated legally for years. While hemp-derived foods currently appear to remain outside the scope of these specific restrictions, the overall policy direction favors a highly concentrated market structure. For international investors and domestic entrepreneurs, this ambiguity and the lack of clear enforcement mechanisms create a risky environment that discourages the innovation and capital needed to scale the industry.

Furthermore, the legislation highlights a paradox in Greece’s approach to medical cannabis, where the state encourages pharmaceutical production while maintaining one of the most restrictive access frameworks in Europe. Patient access remains limited to specific therapeutic indications with no reimbursement mechanisms in place, and only a small number of products are expected to reach the market. As neighboring countries like Germany, Switzerland, the Czech Republic, and Luxembourg adopt more pragmatic regulatory models, Greece faces the risk of losing its competitive advantage. The current focus on tight control over market development may ultimately weaken the country's position in the global cannabinoid economy and reduce wellness options for thousands of consumers.